Pfizer Inc. (NYSE:PFE) Receives $28.12 Consensus Price Target from Brokerages

Key Points

• Pfizer Inc. has been given a consensus rating of "Hold" by analysts, with one sell recommendation, eleven holds, four buys, and two strong buys among the eighteen brokerages covering the stock.
• The company's recent quarterly earnings beat analyst expectations, reporting $0.78 earnings per share against an estimate of $0.58, with revenue of $14.65 billion.
• Pfizer announced a quarterly dividend of $0.43, yielding approximately 7.0%, with a payout ratio of 91.49%.

Pfizer Inc. (NYSE:PFE - Get Free Report) has received a consensus recommendation of "Hold" from the eighteen ratings firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, eleven have given a hold recommendation, four have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $28.1176.

Several equities analysts have recently issued reports on PFE shares. Jefferies Financial Group lifted their price target on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st. Berenberg Bank lowered their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. Morgan Stanley upped their price target on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Citigroup lifted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Finally, Bank of America increased their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th.

Pfizer Price Performance

Pfizer stock traded up $0.27 during trading hours on Wednesday, hitting $24.84. 36,761,269 shares of the company traded hands, compared to its average volume of 44,776,660. Pfizer has a 1-year low of $20.92 and a 1-year high of $30.43. The firm has a market cap of $141.23 billion, a P/E ratio of 13.21, a P/E/G ratio of 0.88 and a beta of 0.55. The firm's 50-day simple moving average is $24.83 and its two-hundred day simple moving average is $24.33. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. During the same period last year, the firm posted $0.60 earnings per share. The business's revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts forecast that Pfizer will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th were paid a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Institutional Investors Weigh In On Pfizer

Several hedge funds have recently modified their holdings of the stock. Gould Capital LLC grew its holdings in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. purchased a new stake in Pfizer in the 1st quarter worth about $27,000. Curio Wealth LLC boosted its position in Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 1,098 shares during the period. North Capital Inc. acquired a new position in shares of Pfizer in the 1st quarter valued at about $28,000. Finally, Bayforest Capital Ltd purchased a new stake in shares of Pfizer in the first quarter worth approximately $28,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.